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Summary
Background Rosacea diagnosis and classification have evolved since the 2002
National Rosacea Society expert panel subtype approach. Several working groups
are now aligned to a more patient-centric phenotype approach, based on an indi-
vidual’s presenting signs and symptoms. However, subtyping is still common-
place across the field and an integrated strategy is required to ensure widespread
progression to the phenotype approach.
Objectives To provide practical recommendations that facilitate adoption of a phe-
notype approach across the rosacea field.
Methods A review of the literature and consolidation of rosacea expert experience.
Results We identify challenges to implementing a phenotype approach in rosacea
and offer practical recommendations to overcome them across clinical practice,
interventional research, epidemiological research and basic science.
Conclusions These practical recommendations are intended to indicate the next
steps in the progression from subtyping to a phenotype approach in rosacea,
with the goals of improving our understanding of the disease, facilitating treat-
ment developments and ultimately improving care for patients with rosacea.
What’s already known about this topic?
• Rosacea diagnosis and classification have evolved from a subtype to a phenotype
approach.
• Adoption of the phenotype approach has begun, but more widespread adoption
and support across the field are required to ensure a complete transition.
What does this study add?
• We offer practical guidance for clinical practice, interventional and epidemiological
research, and basic science, to help overcome challenges and facilitate comprehen-
sive uptake of the phenotype approach in rosacea
Rosacea diagnosis and classification have evolved. In 2002, the
National Rosacea Society (NRS) expert panel proposed diag-
nostic criteria for rosacea and an associated subtype-based clas-
sification that grouped the most common presentations
according to disease features.1 These diagnostic criteria and
the subtype classification have guided the majority of subse-
quent publications on rosacea diagnosis and treatment.2–8
However, progress in rosacea research over the last decade has
revealed important limitations of this approach.9 As a conse-
quence, three working groups [the American Acne and Rosa-
cea Society (AARS), the global rosacea consensus expert panel
(ROSCO) and the NRS] have formalized what many dermatol-
ogists already do in clinical practice and updated the method-
ology for diagnosis based on phenotypes of the disease.9–14
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The recommendations for a phenotype approach to rosacea,
where the disease is diagnosed and classified according to an
individual’s presenting features instead of those grouped by
subtypes, acknowledge the limitations of subtyping, and build
on previous recommendations to propose an approach based
on an individual patient’s presenting signs and symptoms.
Table 1 shows a comparison of rosacea according to the NRS
2002 subtype classification and the aligned 2017 ROSCO and
revised 2017 NRS phenotype recommendations. The features
listed under the 2017 system can be combined into any pre-
sentation, provided the diagnostic criteria are met. Conversely,
the previous 2002 subtype system combined multiple features
into the erythematotelangiectatic, papulopustular, phymatous
and ocular subtypes.1,11,13
Elements of a phenotype approach have been incorporated
into recent national treatment recommendations, which advo-
cate targeted treatment of individual rosacea features.15–18
However, subtyping is still commonplace in numerous recent
publications.19,20 In order to promote wider implementation
of a phenotype approach, it is important first to identify
challenges preventing this transition and then to develop
strategies to address those challenges.21
Common challenges to implementation include: poor sup-
port and organizational structures within the healthcare sys-
tem; insufficient knowledge, awareness or skill; lack of
resources including time; and uncertainty over the legitimacy
of new recommendations.22 In the present publication, we
identify challenges to implementation of a phenotype
approach across clinical practice, interventional research, epi-
demiological research and basic science in rosacea. We then
make practical recommendations to facilitate assessment, man-
agement and research progression inclusive of the individual
experience of disease.
Materials and methods
A panel of four dermatologists defined the framework for possi-
ble recommendation categories pertaining to clinical practice,
interventional research, epidemiological research and basic
science in rosacea. A literature search was performed to assess
the current approach to rosacea practice and research within
these four areas. Hits were limited to articles published between
April 2015 and January 2018 to cover the period after publica-
tion of the most recent Cochrane systematic review on interven-
tions for rosacea.19 The authors identified challenges to
implementation of a phenotype approach based on the literature
search results and their experience in the field. They then consol-
idated and refined their recommendations through discussion.
Challenges
Fifteen years’ usage of the NRS 2002 rosacea diagnostic crite-
ria and subtyping in textbooks, academic papers and podium
presentations has engrained these concepts in dermatology.
There is a need for clinicians, researchers, authors and scien-
tific reviewers to be apprised of current modifications. Until
then, the subtype concept with its shortcomings will persist.
Inconsistent nomenclature is a field-wide issue that con-
founds the reporting of numerous studies. The terms ‘rosacea’
and ‘acne rosacea’ are used variably and often nonspecifically,
as are definitions of certain features (e.g. persistent and tran-
sient erythema can be confounded with perilesional inflamma-
tion). There is a need for better differentiation in research
studies of the phenotype of the patients being studied.
The challenges in interventional research mostly centre on
existing conventions and protocols. As the transition towards a
phenotype approach is a recent development, little documen-
tation exists to demonstrate its benefits and convince stake-
holders of its value. In addition, older treatments assessed
according to subtype in previous literature (e.g. Cochrane sys-
tematic reviews) will be disqualified, while new, smaller stud-
ies may be required to show an effect of a therapy, either
alone or in combination, on specific features.
Industry sponsors of interventional research using subtype-
based measures may be reluctant to replace these with out-
comes for individual features, unless the value has already
Table 1 Summary of recommendations for rosacea diagnosis,
according to the 2002 subtype and 2017 phenotype approaches
NRS 20021
Primary (diagnostic) featuresa Flushing/transient erythema
Nontransient/persistent erythema
Papules and pustules
Telangiectasia
Secondary features Burning/stinging sensation
Oedema
Dry appearance
Ocular manifestations
Plaque
ROSCO 2017/NRS 201711,13
Diagnostic featuresb Persistent centrofacial erythema
with periodic intensification
by potential trigger factors
Phymatous changes
Major featuresc Transient centrofacial erythema
Inflammatory papules/pustules
Telangiectasia
Ocular manifestations
Minor/secondary features Burning/stinging sensation
Oedema
Dry sensation/appearance
According to the 2002 subtyping system, multiple features were
grouped into defined subtypes. The 2017 phenotyping system
allows various combinations of diagnostic, major and minor fea-
tures into an individual phenotype. NRS, National Rosacea Soci-
ety; ROSCO, global ROSacea COnsensus panel. aThe presence of
one or more of these with a central facial distribution is indica-
tive of rosacea. bIndividually diagnostic. cA combination of at
least two is diagnostic, in the absence of a diagnostic feature.
Individual publications also discuss the importance of proper
history taking, exclusion criteria and trigger factors for specific
features.
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been demonstrated. We believe that the phenotype approach
allows investigators to assign outcomes for one or more rosa-
cea features best addressed by investigational treatments, com-
pared with multiple features in some existing scales.
Standardizing these outcome measures would also facilitate
interstudy comparisons and combining of results. Further-
more, improved severity scales that focus on individual fea-
tures should be more accurate than those in current usage,
thereby offering the potential for a smaller trial population to
demonstrate significance. This could translate to lower costs of
trials.
Study protocols are a further challenge for adoption of a
phenotype approach in interventional and epidemiological
research, due to the engrained subtype-based nomenclature.
Some researchers accept implicitly that a singular examination
predicates the features of an individual patient with rosacea;
this fails to account for fluctuation of some features over time
(e.g. papules/pustules or erythema with phyma) and may
provide an incomplete disease representation for the patient.
This is also hindered by the lack of long-term epidemiological
studies in the field. Furthermore, darker skin pigment photo-
types are under-represented in epidemiological studies, due to
difficulties in diagnosis that often fail to account for the pres-
ence of rosacea in these patients.
In basic science, several specific factors also hinder the pro-
gression to a phenotype approach to rosacea. These include
limited funding opportunities, absence of patient registries or
clinical tissue biobanks, and the lack of a satisfactory animal
model for rosacea.
Results
Challenges and recommendations for clinical practice
A phenotype approach to rosacea management could improve
patient outcomes by targeting the aspects most bothersome to
the patient.12 It also facilitates use of combination therapy
when necessary, to address multiple presenting features and
optimize clinical outcomes and quality of life.12 Rosacea treat-
ment is moving towards such an approach, which is now rec-
ommended by several regional and national bodies in clinical
practice.15–18 However, further support is needed to facilitate
its implementation into daily practice.
Assessment of disease severity and patient impact (including
quality of life) would also benefit from a phenotype approach.
Several groups have commented that existing scales for assess-
ing these are not sufficient, including the only rosacea-specific
tool (Rosacea Quality of Life; RosaQoL), which both omits cer-
tain features and lacks indication of a clinically relevant differ-
ence. As such, there is a need for validated tools that are easy
to use in the clinic and address all skin pigment types.9,11,13,23
Recommendations
1. Update the language surrounding rosacea diagnosis and
classification to discontinue the concept of subtyping.
? Includes updated phraseology in textbook revisions,
as well as forthcoming publications.
2. Initiate an international, multisponsor core meeting of
stakeholders to develop a communications plan for the
phenotype concept.
? Supported by specific sessions at the societies’ associ-
ated international congresses to bring the rosacea
phenotyping concept to the forefront, with subse-
quent sessions at national meetings.
3. Educate patients and healthcare providers to raise aware-
ness and improve understanding of the phenotype
nomenclature.
? Education should be targeted to specific groups,
including patient support organizations, dermatolo-
gists and general practitioners.
? Requires promotion to multiple national and interna-
tional organizations for patients with skin disease.
4. Demonstrate the proven clinical value of making the
change to phenotyping and reinforce the shortcomings
of the subtype approach.
? Also requires studies that demonstrate the effect of
different drugs, individually and in combination, on
specific rosacea features, together with appropriate
communication of the results.
5. Develop simple clinical tools for physicians to use with
their patients that are applicable to all skin pigment types.
? Should include clear definitions of individual rosacea
features and their specific burden, to aid the physi-
cian in treating the features most bothersome to the
patient.
? Should align with treatment goals, with clear skin
being a key objective.
? See Appendix S1 in the Supporting Information for a
downloadable checklist to document clinical signs
and symptoms (i.e. the patient’s specific phenotype)
and correlate this with therapeutic approaches.
Challenges and recommendations for interventional
research
Assessment methodologies used in rosacea clinical trials are
variable and could be of higher quality.19,23 The subtype
approach is likely to hinder treatment progress in two ways.
Firstly, a treatment directed at one dimension of a subtype
(e.g. inflammatory papules or pustules in papulopustular rosa-
cea) may fail in clinical trials because it does not address the
subtype’s other dimensions (i.e. persistent erythema).11 Sec-
ondly, the multiple dimensions of a subtype can confound
commonly used rosacea severity scales, as with clinical prac-
tice. In clinical trials, this can interfere with study and assess-
ment of the course of singular disease features.9
© 2018 The Authors. British Journal of Dermatology
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Many clinical trials in rosacea still recruit patients using sub-
type-based inclusion criteria and assess treatment outcomes
according to those subtypes (for example, using the NRS
Rosacea Clinical Scorecard).19 However, although some more
recent studies have still recruited patients by subtype, they
have assessed therapeutic response by change in individual
features.24–27 This is a positive step towards a phenotype
approach.
Recommendations
1. Establish credible, standardized clinical and patient-
reported measures for the most common features to
make them acceptable to researchers, industry and regu-
latory authorities.
? Industry may be especially interested in moving for-
ward new drug entities to address specific signs and
symptoms instead of the multiple dimensions
required with subtypes.
2. Develop and publish real-life examples of phenotype use
in interventional research, to validate the approach and
demonstrate best practice throughout the field.
? Could be based on the five-part AARS series, suggest-
ing that a phenotype evaluation of rosacea correlates
with therapy.10,28–31
? Enhance with the support of a larger group of inter-
ested researchers and clinicians.
Challenges and recommendations for epidemiological
research
Epidemiological studies in rosacea provide widely varying dis-
ease prevalence estimates. Beyond valid differences relating to
location and population differences, this variation may be a
result of differences in case determination and study design,
and variable assessment of individual features due to differ-
ences in skin pigment type.14
Characterizing by subtype confounds epidemiological
studies because many patients present with varied features,
so are inadequately described. For example, there is no sub-
type for a patient presenting solely with persistent centrofa-
cial erythema without transient erythema and flushing, or
vice versa. Similarly, a patient presenting with fixed ery-
thema, inflammatory papules and pustules and telangiectasia
could fall into both the erythematotelangiectatic and papulo-
pustular categories, and so might be counted twice.9 Fur-
thermore, certain features can spontaneously remit and
recur, which may result in the patient being classified in
multiple subtype categories dependent on the time of obser-
vation.32
Refining diagnostic criteria based on a phenotype approach
could improve the consistency and quality of epidemiological
data, which would continue to benefit rosacea diagnosis and
overall disease management.14
Recommendations
1. Facilitate longitudinal epidemiological studies in rosacea
that consider the potential for fluctuation of certain fea-
tures.
? There would be great value in extension to a global
registry, which would provide longitudinal real-
world evidence to bolster epidemiological data and a
phenotype treatment approach.
2. Include and support regional groups from all continents
in epidemiological studies, to ensure representation of all
skin pigment types.
Challenges and recommendations for basic science
Despite ongoing research, the pathophysiology of rosacea
remains uncertain. Cutaneous rosacea subtypes demonstrate
both differences and overlap in histological, immunohistologi-
cal and gene expression markers. As such, there is limited
information on molecular markers responsible for the initia-
tion and perpetuation of rosacea’s various cutaneous fea-
tures.9,33–35 Therefore, subtype classification may be hindering
biomarker identification for individual features.
Recommendations
1. Work towards highlighting the need for national initia-
tives to support research in rosacea.
? For example, the National Institutes for Health
Request for Applications.
2. Extend clinical practice updates that emphasize phenotype
nomenclature to basic science.
? Would be of similar benefit in standardizing assess-
ments.
3. Reinforce the concept of phenotype variation over time,
as with epidemiological research.
? Would encourage specimen collections at multiple
time points to assess the chronic nature of the dis-
ease.
4. Interrogate existing data to unmask key specific factors in
rosacea pathophysiology and identify which treatments
have the largest or fastest impact on disease.
Discussion
Herein we have discussed strategies to support the phenotype
approach in rosacea across clinical practice, interventional
and epidemiological research, and basic science. Several
strategies span multiple areas, which reflects the need for an
integrated approach to ensure consistent and comprehensive
uptake.
© 2018 The Authors. British Journal of Dermatology
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Audit and feedback lead to small but potentially important
improvements in professional practice.36 It is therefore impor-
tant to measure the effectiveness of the phenotype approach as
it becomes more widely used, which will both enable sharing
of successes to promote a virtuous circle of uptake and iden-
tify areas for improvement. In studies assessing the effective-
ness of clinical guideline dissemination and implementation,
the most widely used strategies for measuring change were
medical record audit, computerized databases and health prac-
titioner questionnaire or interview.37 These align with several
recommendations from the World Health Organization to
measure specific behaviour change strategies.38
The Expert Recommendations for Implementing Change
project has compiled a number of implementation strategies
for guideline implementation.39 We have identified those
most relevant to the rosacea field and summarized them in
Table 2, together with comment on the context of each and
potential strategies to measure effectiveness.
Our recommendations are limited by the fact that this is an
evolving field of inquiry, meaning future advances may
inform modification of signs and symptoms, and subsequent
adjustment to our suggested language updates and tools.
Furthermore, even given an objective tool, the severity of
some signs can be subjective; for example, some cultures may
consider persistent mild centrofacial erythema presenting as
‘rosy cheeks’ to be a normal or healthy variation. There are
also limitations in the use of persistent centrofacial erythema
as a definitive diagnostic feature in dark skin phototypes,
which will require specific guidance from future work to
ensure consistent diagnosis and classification across the patient
spectrum.
The transition to a phenotype approach in rosacea is under-
way; however, there is still significant work to be done to
ensure a comprehensive uptake. These practical recommenda-
tions are intended to indicate the next steps in this process,
with the goals of improving our understanding of the disease,
facilitating treatment developments, and ultimately improving
care for patients with rosacea.
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Table 2 Key strategies for implementing change from the Expert Recommendations for Implementing Change and their context in rosacea
Key activities for strategy implementation39
Relevance to rosacea and current status
Underway Future work
Build a coalition: recruit and cultivate
relationships with partners in the
implementation effort
Global, regional and national
working groups are becoming
aligned to adoption of a phenotype
approach
Instigate a core meeting at international
congresses via partnerships with
international or regional societies, with
cascades down to national meetings
Develop an implementation glossary:
develop and distribute a list of terms
describing the innovation, implementation
and stakeholders in the organizational
change
Not applicable Develop an online resource of ‘how to
implement the rosacea phenotype
approach’. This should be freely available,
referenceable and accessible. Could
integrate with a feedback system (see
‘audit and provide feedback’, below)
Distribute educational materials (including
guidelines, manuals and toolkits) in
person, by mail and/or electronically
Not applicable Develop standard training materials on the
new approach for local adaptation and
adoption, ideally with endorsement from
local or regional associations
Promote adaptability: identify the ways in
which a clinical innovation can be tailored
to meet local needs and clarify which
elements of the innovation must be
maintained to preserve fidelity
Global recommendations now exist
to consider all skin pigment types
when developing tools and
diagnostic recommendations11
Translate global recommendations and make
widely available. Gain feedback from local
associations and working groups to
identify specific needs
Conduct educational meetings: hold
meetings targeted towards different
stakeholder groups (e.g. providers,
administrators, other organizational
groups, and community, patient/consumer
and family stakeholders) to teach them
about the clinical innovation
Not applicable Initiate educational meetings targeted to
specific groups; could be online or face to
face. This should consider information
sharing between groups to facilitate an
integrated community. Initiate meetings
with stakeholders to test-drive
implementation tools
Audit and provide feedback: collect and
summarize clinical performance data over a
specified time period and give them to
clinicians and administrators to monitor,
evaluate and modify provider behaviour
Not applicable Develop tools allowing ongoing audit of
clinical practice behaviour; could be
simple, practical resources for both online
and offline use, up to a global clinical
registry
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